Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Envisagenics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Envisagenics

Envisagenics

Series A

Envisagenics, Inc.: A New York-based biomedical data firm using AI for drug discovery and RNA splicing analytics.

HQ
New York City, NY, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Envisagenics, Inc. is a biomedical data analysis company based in New York that leverages artificial intelligence for drug discovery and RNA splicing analytics. The company's core mission is to harness the power of AI to develop therapeutic solutions, focusing on RNA target identification and SSO (splice-switching oligonucleotide) therapeutic development. Envisagenics serves the healthcare sector by providing advanced software tools that facilitate the discovery of novel treatments.

Envisagenics has made significant strides in validating its AI/ML approach for RNA target identification, collaborating with notable entities such as Cancer Research Horizons and Queen Mary University. These achievements underscore the company's impact on the field of biomedical research and its potential to revolutionize therapeutic development.

Envisagenics - Similar Companies

Enveda Biosciences logo

Enveda Biosciences

envedabio.com

Srnalytics logo

Srnalytics

srnalytics.com

Atomic AI logo

Atomic AI

atomic.ai

Owkin logo

Owkin

owkin.com

Ensem Therapeutics logo

Ensem Therapeutics

ensemtx.com

InterVenn Biosciences logo

InterVenn Biosciences

intervenn.com

Verge Genomics logo

Verge Genomics

vergegenomics.com

Cognaisent logo

Cognaisent

cognaisent.com

Anagenex logo

Anagenex

anagenex.com

Entwine Bio logo

Entwine Bio

entwine.bio

Inceptive logo

Inceptive

inceptive.life

Enable Medicine logo

Enable Medicine

enablemedicine.com

Insilico Medicine logo

Insilico Medicine

insilico.com

Exai Bio logo

Exai Bio

exai.bio

Panorama Medicine logo

Panorama Medicine

Envisagenics - Quick Facts

Who are Envisagenics' competitors?

Companies similar to Envisagenics include Enveda Biosciences, Srnalytics, Atomic AI and Owkin.

When was Envisagenics founded?

Envisagenics was founded in 2014.

Where is Envisagenics' headquarters located?

Envisagenics' headquarters is located in New York City, NY, US.

How much has Envisagenics raised to-date?

As of May 11, 2023, Envisagenics has raised a total of $27.1M (USD).

How many employees does Envisagenics have?

Envisagenics has 47 employees as of Feb 5, 2024.

Envisagenics - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • United States
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Discovery
Tags
  • AI Operations
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software